{"entity":{"id":"suzhou-bluehorse-therapeutics","kind":"company","name":"Suzhou BlueHorse Therapeutics","aka":["Suzhou Lanma Biotechnology"],"tldr":"Suzhou BlueHorse Therapeutics is a China-based cell therapy company that leads 2 cancer trials in OnCo, testing the tumour-infiltrating lymphocyte product LM103 in non-small-cell lung cancer and melanoma.","summary":"Suzhou BlueHorse Therapeutics is a Suzhou-based cell therapy developer. The ClinicalTrials.gov registry lists it as lead sponsor of phase 2 trials of LM103, a tumour-infiltrating lymphocyte (TIL) product, in non-small-cell lung cancer and melanoma. Its website could not be reached, so company facts here are limited to the registry. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT07444437 (phase 2, A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung C...) and NCT07310784 (phase 2, A Phase II Trial of LM103 in Advanced Melanoma). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov: trials led by Suzhou BlueHorse Therapeutics","url":"https://clinicaltrials.gov/search?lead=Suzhou%20BlueHorse%20Therapeutics%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["dacarbazine","temozolomide","paclitaxel","carboplatin","cisplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07444437","nct07310784"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Suzhou","country":"CN","companyType":"cell-therapy","investors":[],"funding":[]},"route":"/companies/suzhou-bluehorse-therapeutics/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"dacarbazine","kind":"drug","name":"Dacarbazine","route":"/drugs/dacarbazine/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}],"trial":[{"id":"nct07444437","kind":"trial","name":"A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer","route":"/trials/nct07444437/"},{"id":"nct07310784","kind":"trial","name":"A Phase II Trial of LM103 in Advanced Melanoma","route":"/trials/nct07310784/"}]}}